Unknown

Dataset Information

0

Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.


ABSTRACT: The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled trial of daily acyclovir for genital herpes (HSV-2) suppression among HIV-1/HSV-2 co-infected persons to reduce HIV-1 transmission to their HIV-1 susceptible partners, which requires recruitment of HIV-1 serodiscordant heterosexual couples. We describe the baseline characteristics of this cohort.HIV-1 serodiscordant heterosexual couples, in which the HIV-1 infected partner was HSV-2 seropositive, had a CD4 count >or=250 cells/mcL and was not on antiretroviral therapy, were enrolled at 14 sites in East and Southern Africa. Demographic, behavioral, clinical and laboratory characteristics were assessed.Of the 3408 HIV-1 serodiscordant couples enrolled, 67% of the HIV-1 infected partners were women. Couples had cohabitated for a median of 5 years (range 2-9) with 28% reporting unprotected sex in the month prior to enrollment. Among HIV-1 susceptible participants, 86% of women and 59% of men were HSV-2 seropositive. Other laboratory-diagnosed sexually transmitted infections were uncommon (<5%), except for Trichomonas vaginalis in 14% of HIV-1 infected women. Median baseline CD4 count for HIV-1 infected participants was 462cells/mcL and median HIV-1 plasma RNA was 4.2 log(10) copies/mL. After adjusting for age and African region, correlates of HIV-1 RNA level included male gender (+0.24 log(10) copies/mL; p<0.001) and CD4 count (-0.25 and -0.55 log(10) copies/mL for CD4 350-499 and >500 relative to <350, respectively, p<0.001).The Partners Study successfully enrolled a cohort of 3408 heterosexual HIV-1 serodiscordant couples in Africa at high risk for HIV-1 transmission. Follow-up of this cohort will evaluate the efficacy of acyclovir for HSV-2 suppression in preventing HIV-1 transmission and provide insights into biological and behavioral factors determining heterosexual HIV-1 transmission.ClinicalTrials.gov NCT00194519.

SUBMITTER: Lingappa JR 

PROVIDER: S-EPMC2671170 | biostudies-literature | 2009

REPOSITORIES: biostudies-literature

altmetric image

Publications

Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.

Lingappa Jairam R JR   Kahle Erin E   Mugo Nelly N   Mujugira Andrew A   Magaret Amalia A   Baeten Jared J   Bukusi Elizabeth A EA   Cohen Craig R CR   Katabira Elly E   Ronald Allan A   Kiarie James J   Farquhar Carey C   Stewart Grace John GJ   Makhema Joseph J   Essex M M   Were Edwin E   Fife Kenneth K   Debruyn Guy G   Gray Glenda G   McIntyre James J   Manongi Rachel R   Kapiga Saidi S   Coetzee David D   Allen Susan S   Inambao Mubiana M   Kayitenkore Kayitesi K   Karita Etienne E   Kanweka William W   Delany Sinead S   Rees Helen H   Vwalika Bellington B   Coombs Robert W RW   Morrow Rhoda R   Whittington William W   Corey Lawrence L   Wald Anna A   Celum Connie C  

PloS one 20090430 4


<h4>Background</h4>The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled trial of daily acyclovir for genital herpes (HSV-2) suppression among HIV-1/HSV-2 co-infected persons to reduce HIV-1 transmission to their HIV-1 susceptible partners, which requires recruitment of HIV-1 serodiscordant heterosexual couples. We describe the baseline characteristics of this cohort.<h4>Methods</h4>HIV-1 serodiscordant heterosexual couples, in which the HIV-1 infected p  ...[more]

Similar Datasets

| S-EPMC3762386 | biostudies-literature
| S-EPMC4026368 | biostudies-literature
| S-EPMC4026137 | biostudies-literature
| S-EPMC6211178 | biostudies-literature
| S-EPMC2788224 | biostudies-literature
| S-EPMC2570252 | biostudies-literature
| S-EPMC3869741 | biostudies-literature
| S-EPMC3202340 | biostudies-literature
| S-EPMC3187805 | biostudies-literature
| S-EPMC3512641 | biostudies-other